Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ADALIMUMAB Cause False negative investigation result? 9 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 9 reports of False negative investigation result have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.0% of all adverse event reports for ADALIMUMAB.

9
Reports of False negative investigation result with ADALIMUMAB
0.0%
of all ADALIMUMAB reports
0
Deaths
5
Hospitalizations

How Dangerous Is False negative investigation result From ADALIMUMAB?

Of the 9 reports, 5 (55.6%) required hospitalization, and 1 (11.1%) were considered life-threatening.

Is False negative investigation result Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 9 reports have been filed with the FAERS database.

What Other Side Effects Does ADALIMUMAB Cause?

Drug ineffective (71,926) Pain (37,514) Arthralgia (35,592) Rheumatoid arthritis (29,817) Fatigue (29,420) Injection site pain (28,679) Headache (19,891) Nausea (19,299) Rash (18,690) Pain in extremity (18,319)

What Other Drugs Cause False negative investigation result?

HISTAMINE (140) ALLERGENIC EXTRACT- PEANUT ARACHIS HYPOGAEA (131) FENTANYL (24) CLONAZEPAM (21) CARYA ILLINOINENSIS POLLEN (18) PISTACHIO (15) EMTRICITABINE\TENOFOVIR DISOPROXIL (13) PREDNISOLONE (13) METHOTREXATE (10) RITUXIMAB (10)

Which ADALIMUMAB Alternatives Have Lower False negative investigation result Risk?

ADALIMUMAB vs ADALIMUMAB-AACF ADALIMUMAB vs ADALIMUMAB-AATY ADALIMUMAB vs ADALIMUMAB-ADAZ ADALIMUMAB vs ADALIMUMAB-ADBM ADALIMUMAB vs ADALIMUMAB-AFZB

Related Pages

ADALIMUMAB Full Profile All False negative investigation result Reports All Drugs Causing False negative investigation result ADALIMUMAB Demographics